(NYSEMKT: NNVC) Nanoviricides's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.96%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 31.71%.
Nanoviricides's earnings in 2026 is -$8,090,991.On average, 4 Wall Street analysts forecast NNVC's earnings for 2027 to be -$10,156,772, with the lowest NNVC earnings forecast at -$9,758,468, and the highest NNVC earnings forecast at -$10,455,501. On average, 3 Wall Street analysts forecast NNVC's earnings for 2027 to be -$7,727,979, with the lowest NNVC earnings forecast at -$7,424,921, and the highest NNVC earnings forecast at -$7,955,273.
In 2028, NNVC is forecast to generate -$9,494,374 in earnings, with the lowest earnings forecast at -$9,122,046 and the highest earnings forecast at -$9,773,621.